[go: up one dir, main page]

JP2004002230A - Method for producing microaqueous benzimidazole compound - Google Patents

Method for producing microaqueous benzimidazole compound Download PDF

Info

Publication number
JP2004002230A
JP2004002230A JP2002160105A JP2002160105A JP2004002230A JP 2004002230 A JP2004002230 A JP 2004002230A JP 2002160105 A JP2002160105 A JP 2002160105A JP 2002160105 A JP2002160105 A JP 2002160105A JP 2004002230 A JP2004002230 A JP 2004002230A
Authority
JP
Japan
Prior art keywords
compound
benzimidazole
microaqueous
water
hydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002160105A
Other languages
Japanese (ja)
Other versions
JP4115751B2 (en
Inventor
Tadashi Aihara
相原 廉
Eiko Hiroshige
広重 栄子
Kiyonori Yokogoshi
横越 清範
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Permachem Asia Ltd
Original Assignee
Permachem Asia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Permachem Asia Ltd filed Critical Permachem Asia Ltd
Priority to JP2002160105A priority Critical patent/JP4115751B2/en
Publication of JP2004002230A publication Critical patent/JP2004002230A/en
Application granted granted Critical
Publication of JP4115751B2 publication Critical patent/JP4115751B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<P>PROBLEM TO BE SOLVED: To provide a method for producing a microaqueous benzimidazole compound by which the microaqueous benzimidazole compound useful as a medicine, especially an antiulcer agent can be obtained as a stable microaqueous substance in good purity and high yield by a simple method. <P>SOLUTION: The method for producing the microaqueous benzimidazole compound comprises dissolving a solvate and/or a hydrate of a compound represented by formula (I) in a soluble solvent, crystallizing the compound with alkaline water at pH≥8 and drying the resultant crystal at a low temperature of <50°C. <P>COPYRIGHT: (C)2004,JPO

Description

【0001】
【発明の属する技術分野】
本発明は、医薬品のうち、特に抗潰瘍剤として有用である微水ベンズイミダゾール系化合物の製法に関し、詳しくは、該化合物を簡便な方法で安定な微水物とし、しかも該化合物を純度よく、かつ高収率で得ることのできる製法に関する。
【0002】
【従来の技術】
ベンズイミダゾール系化合物のうち、2−〔(3−メチル−4−《2,2,2−トリフルオロエトキシ》ピリジン−2−イル)メチルスルフィニル〕ベンズイミダゾールは、慣用名をランソプラゾールといい、医薬品のうち、特に抗潰瘍剤として有用であるとされている。
従来、これらのベンズイミダゾール系化合物については、特開平1−131176号公報、特公平2−44473号公報、同3−38247号公報、同6−86444号公報、特開平10−195068号公報などに、その物質や製造法、用途などが示されている。
【0003】
ベンズイミダゾール系化合物は、製造工程や精製工程の際に、溶媒和物および/または水和物を形成し易いという性質を有し、上記の製造法によれば本化合物は溶媒和物および/または水和物という形態で得られている。
しかし、溶媒や、特に水を取り込んだ本化合物の結晶は、経時安定性が悪く、分解が起き易いという問題を抱えている。
他方、本化合物の溶媒和物および/または水和物を加熱乾燥により脱水する際、50℃付近以上から本化合物の熱分解が起こり、かつ減圧下による低温乾燥のみでは溶媒や水を除去することが困難である。
【0004】
これを解決する方法として、特開平10−195068号公報には、ベンズイミダゾール系化合物の溶媒和物・水和物を、水中での懸濁操作からなる脱溶媒処理に付し、実質的に溶媒を含まない該化合物を製造する方法が示されている。
また、この実施例では、「エタノール・水混和溶液にアンモニア水を加え、この溶液を予め60℃に加熱したところにベンズイミダゾール系化合物を加えて溶解する。これを熱時濾過して不溶物を除去し、得られた濾液を氷冷してベンズイミダゾール系化合物のエタノール和物・水和物結晶を得る。次いで、この結晶を水に懸濁し、30℃にて1時間撹拌後、濾取・水洗し、40℃にて10時間真空乾燥することにより該化合物の実質的無溶媒物を得る」としている。
【0005】
【発明が解決しようとする課題】
しかし、上記の方法を忠実に実施しようとするとき、
(1)ベンズイミダゾール系化合物を溶解する溶液を60℃に加熱することにより、該化合物が分解してしまう可能性がある、
(2)該化合物のエタノール和物・水和物からなる結晶を水に懸濁し、30℃において1時間もの長時間に渡って撹拌する際にも、該化合物が分解してしまう可能性がある、
(3)上記(1)および(2)から、純度や収率の低下を招くおそれがある、
(4)該化合物の結晶を、エタノール和物・水和物として一度取り出し、再度、脱溶媒処理に付さねばならないなど、煩雑な工程を要する、
などの問題がある。
【0006】
【課題を解決するための手段】
本発明者らは、上記のような状況に鑑み、ベンズイミダゾール系化合物の溶媒和物・水和物について、これがさらなる溶媒和物・水和物を経由することなく、該化合物の微水物を直接得るための方法について鋭意検討を重ねた結果、該化合物の溶媒和物および/または水和物を可溶性の溶媒に溶解し、アルカリ性水により該化合物の結晶を析出させ、低温乾燥するという工程、すなわち50℃付近以上の温度をかけず、かつ簡便な工程により、含水分が0.1%以下の該化合物の微水結晶を純度・収率よく製造することができることを見出し、本発明を完成するに至った。
【0007】
すなわち、本発明は、式(I)で示される化合物の溶媒和物および/または水和物を、可溶性の溶媒に溶解し、アルカリ性水により該化合物を結晶化させ、低温乾燥することを特徴とする微水ベンズイミダゾール系化合物の製法をその要旨とする。
【0008】
【化2】

Figure 2004002230
【0009】
このとき用いる可溶性の溶媒は、ジメチルホルムアミドおよび/またはテトラハイドロフランであることが好ましく、また上記の低温乾燥時の温度は50℃未満であることが好ましい。
【0010】
本発明において、式(I)で示される化合物、すなわち2−〔(3−メチル−4−《2,2,2−トリフルオロエトキシ》ピリジン−2−イル)メチルスルフィニル〕ベンズイミダゾールは、薬学的に許容される塩についても含まれるものとする。
この塩としては、例えば、無機塩基との塩、有機塩基との塩、塩基性アミノ酸との塩などが挙げられる。
無機塩基との塩の好適な例としては、例えば、ナトリウム塩、カリウム塩などのアルカリ金属塩;カルシウム塩、マグネシウム塩などのアルカリ土類金属塩;アンモニウム塩などが挙げられる。
有機塩基との塩の好適な例としては、例えば、トリメチルアミン、トリエチルアミン、ピリジン、ピコリン、エタノールアミン、ジエタノールアミン、トリエタノールアミン、ジシクロヘキシルアミン、N,N’−ジベンジルエチレンジアミンなどとの塩が挙げられる。
塩基性アミノ酸との塩の好適な例としては、例えば、アルギニン、リジン、オルニチンなどとの塩が挙げられる。
好ましくは、アルカリ金属塩、またはアルカリ土類金属塩であり、特に好ましくはナトリウム塩である。
【0011】
式(I)で示される化合物の溶媒和物および/または水和物における溶媒和物は、アルコール和物などが挙げられ、なかでもエタノール和物が一般的であるが、さらに水和物を取り込んだ水和・アルコール和物として結晶化していることが多い。より具体的には、例えば、前記の特開平1−131176号公報に記載の方法に従って、含水エタノールから再結晶精製して得られる水−エタノール溶媒和物結晶などが挙げられる。
【0012】
本発明に用いる可溶性の溶媒とは、式(I)で示される化合物の溶媒和物および/または水和物を溶解できるものであればいかなるものでもよいが、アルコール類は再度アルコール和物やアルコール和・水和物になってしまうため、アルコール以外の溶媒がよく、なかでもジメチルホルムアミド、テトラハイドロフランなどが好ましく用いられる。これらの溶媒は単独で用いてもよいし、組み合わせて用いてもよい。
【0013】
可溶性の溶媒は、式(I)で示される化合物の溶媒和物および/または水和物100重量部に対し、100〜1000重量部、好ましくは300〜900重量部程度用い、室温にて撹拌すれば十分に上記の化合物がこれに溶解する。
溶媒の量がこれより多いと、該化合物を溶解させるのには支障はないが、取り扱いや経済性の面で好ましくなく、これより少ないと、該化合物を十分に溶解することができないことがある。
【0014】
本発明に用いるアルカリ性水のpHは8以上であればよいが、好ましくはpH8.0〜9.5の弱アルカリ性である。
このアルカリ性水は、具体的には、アンモニア水の他、無機アルカリや有機アルカリ化合物の水溶液が好適に用いられる。
アルカリ性水が、pH9.5より高いアルカリ性であると、該化合物を可溶性の溶媒から析出させるのには支障はないが、析出させた後の結晶の洗浄や取り扱いが煩雑になることがあり、pH8.0未満であると、可溶性の溶媒に溶解した該化合物を十分に析出できないことがあり、また該化合物の分解が起こり純度が低下することがある。
【0015】
アルカリ性水の温度は、室温でも析出に差し支えはないが、効率的には、0〜15℃程度に冷却して用いるとよい。
室温より高温であると、該化合物の析出効率が低下し、収率を下げることがある。なお、0℃未満であると、該化合物を析出するのには支障はないが、析出効果が飽和してしまい、熱経済的に不利となることがある。
【0016】
上記pHで上記温度のアルカリ性水は、式(I)で示される化合物の溶媒和物および/または水和物100重量部に対し、200〜10,000重量部、好ましくは4,000〜8,000重量部程度用いる。
アルカリ性水の量が10,000重量部を超えると、該化合物を析出させるのには支障はないが、取り扱いや経済性の面から好ましくなく、200重量部未満であると、十分に該化合物を析出させることができないことがあり、可溶性の溶媒中に該化合物が残存するために収率の低下を招くことがある。
ベンズイミダゾール系化合物の溶媒和物および/または水和物が溶解した可溶性の溶媒に、上記のアルカリ性水を加えることにより、該化合物の微水結晶が析出する。
【0017】
析出した結晶を濾過などにより分取し、必要に応じて水などで洗浄した後、50℃未満において、低温乾燥することにより、含水分0.1%以下の微水ベンズイミダゾール系化合物の白色結晶を得ることができる。
乾燥温度が50℃以上であると、該化合物の分解を生じる可能性が高くなって純度が低下することがあり、また余り低温過ぎると、乾燥時間が長くなることがあったり、また冷熱確保にコストがかかることがあるため、室温程度を下限とすることが好ましい。
好適な乾燥温度は、35〜45℃程度である。
この乾燥は、減圧下で行うことが、乾燥時間をより短縮する上で好ましく、減圧の程度は1〜100mmHg、好ましくは5〜30mmHg程度が適している。
このような温度、減圧下での乾燥時間は、8〜14時間程度であれは十分である。
【0018】
【実施例】
実施例1
水分1.5%の2−〔(3−メチル−4−《2,2,2−トリフルオロエトキシ》ピリジン−2−イル)メチルスルフィニル〕ベンズイミダゾール10gを、ジメチルホルムアミド60gに室温にて撹拌して溶解した。
この溶液を濾過して不溶物を除去し、得られた濾液を、pH約9で約10℃のアンモニア水600gに撹拌しながら注ぎ、析出結晶を濾取した。
結晶を水50gで洗浄した後、15mmHg程度の減圧下、40℃で、12時間乾燥することにより、2−〔(3−メチル−4−《2,2,2−トリフルオロエトキシ》ピリジン−2−イル)メチルスルフィニル〕ベンズイミダゾールの白色結晶を9.3g得た〔脱水物(原体《結晶》の水分を除去したもの)換算収率94.4%〕。
得られた白色結晶の物性は次の通りであった。
【0019】
融点:177.4℃(分解)
水分:0.04%(平沼製作所社製商品名“AQV−7S型”でのカールフィッシャー電量法)
Figure 2004002230
なお、上記の元素分析値において、フッ素の定量のみについては、酸素フラスコ燃焼法により行った測定値である。
【0020】
実施例2
水分0.9%の2−〔(3−メチル−4−《2,2,2−トリフルオロエトキシ》ピリジン−2−イル)メチルスルフィニル〕ベンズイミダゾールのエタノール和・水和物20gを、テトラハイドロフラン150gに35℃にて撹拌して溶解した。
この溶液を濾過して不溶物を除去し、得られた濾液を、pH約9.5で、約10℃のアンモニア水1200gに撹拌しながら注ぎ、析出結晶を濾取した。
結晶を水120gで洗浄した後、約15mmHgの減圧下、45℃で乾燥することにより、2−〔(3−メチル−4−《2,2,2−トリフルオロエトキシ》ピリジン−2−イル)メチルスルフィニル〕ベンズイミダゾールの白色結晶を9.3g得た〔脱水物換算収率94.4%〕。
【0021】
得られた白色結晶について、実施例1と同様に含水分を測定したところ、0.03%であった。
【0022】
【発明の効果】
本発明の微水ベンズイミダゾール系化合物の製法によれば、温度を必要以上に高温にすることなく、従ってベンズイミダゾール系化合物の分解を極力抑えることで、含水分0.1%以下の該化合物を純度よく、かつ極めて高収率で製造することができる。
しかも、その製造工程は、極めて簡便であり、工業的に有意義である。[0001]
TECHNICAL FIELD OF THE INVENTION
The present invention relates to a method for producing a benzimidazole-based compound in water, which is particularly useful as an anti-ulcer agent, among pharmaceuticals, in particular, to convert the compound into a stable microhydrate in a simple method, and to purify the compound with high purity. And a production method which can be obtained in high yield.
[0002]
[Prior art]
Among the benzimidazole compounds, 2-[(3-methyl-4-<< 2,2,2-trifluoroethoxy] pyridin-2-yl) methylsulfinyl] benzimidazole is commonly called lansoprazole and is used in pharmaceuticals. Among them, it is particularly useful as an anti-ulcer agent.
Conventionally, these benzimidazole compounds are described in JP-A-1-131176, JP-B-2-44473, JP-B3-38247, JP-A-6-86444, JP-A-10-195068 and the like. , Their substances, manufacturing methods, applications, etc. are indicated.
[0003]
The benzimidazole-based compound has a property of easily forming a solvate and / or hydrate in a production step or a purification step, and according to the above production method, the present compound is a solvate and / or hydrate. It is obtained in the form of a hydrate.
However, the crystals of the present compound in which a solvent, especially water is incorporated, have a problem that the stability over time is poor and the decomposition is likely to occur.
On the other hand, when the solvate and / or hydrate of the present compound is dehydrated by heating and drying, thermal decomposition of the present compound occurs from about 50 ° C. or higher, and the solvent and water are removed only by low-temperature drying under reduced pressure. Is difficult.
[0004]
As a method for solving this, JP-A-10-195068 discloses that a solvate / hydrate of a benzimidazole compound is subjected to a desolvation treatment comprising a suspension operation in water to substantially remove the solvent. A method for preparing the compound free of is shown.
Also, in this example, "Ammonia water is added to the ethanol / water mixed solution, and the solution is heated in advance to 60 ° C., and the benzimidazole compound is added and dissolved. This is filtered while hot to remove insoluble matter. The obtained filtrate is ice-cooled to obtain ethanolic hydrate / hydrate crystals of a benzimidazole compound, which are then suspended in water, stirred at 30 ° C. for 1 hour, and filtered. It is washed with water and vacuum dried at 40 ° C. for 10 hours to obtain a substantially solvent-free product of the compound ”.
[0005]
[Problems to be solved by the invention]
However, when trying to faithfully implement the above method,
(1) By heating a solution in which a benzimidazole-based compound is dissolved to 60 ° C., the compound may be decomposed.
(2) The compound may be decomposed even when a crystal composed of an ethanol solvate / hydrate of the compound is suspended in water and stirred at 30 ° C. for as long as 1 hour. ,
(3) From the above (1) and (2), there is a possibility that the purity or the yield may be reduced.
(4) complicated steps are required, such as taking out the crystal of the compound once as an ethanol solvate / hydrate and again subjecting it to a desolvation treatment;
There is such a problem.
[0006]
[Means for Solving the Problems]
In view of the situation as described above, the present inventors have found that a solvate / hydrate of a benzimidazole-based compound does not pass through a further solvate / hydrate, and that As a result of intensive studies on a method for directly obtaining the compound, a step of dissolving a solvate and / or hydrate of the compound in a soluble solvent, precipitating crystals of the compound with alkaline water, and drying at a low temperature, That is, they have found that fine water crystals of the compound having a water content of 0.1% or less can be produced with good purity and yield by a simple process without applying a temperature of around 50 ° C. or more, and completed the present invention. I came to.
[0007]
That is, the present invention is characterized in that a solvate and / or hydrate of the compound represented by the formula (I) is dissolved in a soluble solvent, the compound is crystallized with alkaline water, and dried at a low temperature. The gist of the present invention is a method for producing a slightly water benzimidazole compound.
[0008]
Embedded image
Figure 2004002230
[0009]
The soluble solvent used at this time is preferably dimethylformamide and / or tetrahydrofuran, and the temperature during the low-temperature drying is preferably less than 50 ° C.
[0010]
In the present invention, the compound represented by the formula (I), that is, 2-[(3-methyl-4-<< 2,2,2-trifluoroethoxy >> pyridin-2-yl) methylsulfinyl] benzimidazole is used as a pharmaceutical. And the salts that are acceptable.
Examples of the salt include a salt with an inorganic base, a salt with an organic base, and a salt with a basic amino acid.
Preferable examples of the salt with an inorganic base include an alkali metal salt such as a sodium salt and a potassium salt; an alkaline earth metal salt such as a calcium salt and a magnesium salt; an ammonium salt.
Preferred examples of the salt with an organic base include, for example, salts with trimethylamine, triethylamine, pyridine, picoline, ethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, N, N'-dibenzylethylenediamine, and the like.
Suitable examples of the salt with a basic amino acid include, for example, salts with arginine, lysine, ornithine and the like.
Preferably, it is an alkali metal salt or an alkaline earth metal salt, particularly preferably a sodium salt.
[0011]
The solvate and / or hydrate of the compound represented by the formula (I) includes an alcoholate and the like, and among them, an ethanol solvate is generally used. It is often crystallized as a hydrate or alcohol solvate. More specifically, for example, water-ethanol solvate crystals obtained by recrystallization and purification from aqueous ethanol according to the method described in the above-mentioned JP-A-1-131176 can be mentioned.
[0012]
The soluble solvent used in the present invention may be any solvent as long as it can dissolve a solvate and / or hydrate of the compound represented by the formula (I). Solvents other than alcohols are preferred because they are hydrated and hydrated, and among them, dimethylformamide, tetrahydrofuran and the like are preferably used. These solvents may be used alone or in combination.
[0013]
The soluble solvent is used in an amount of 100 to 1,000 parts by weight, preferably about 300 to 900 parts by weight, based on 100 parts by weight of the solvate and / or hydrate of the compound represented by the formula (I), and stirred at room temperature. The above compounds are sufficiently soluble in this.
If the amount of the solvent is larger than this, there is no problem in dissolving the compound, but it is not preferable in terms of handling and economy, and if it is smaller than this, the compound may not be sufficiently dissolved. .
[0014]
The pH of the alkaline water used in the present invention may be at least 8, but is preferably weakly alkaline at pH 8.0 to 9.5.
As the alkaline water, specifically, an aqueous solution of an inorganic alkali or an organic alkali compound is suitably used in addition to ammonia water.
When the alkaline water is alkaline having a pH higher than 9.5, there is no problem in precipitating the compound from a soluble solvent, but washing and handling of the crystal after the precipitation may be complicated, and the pH of the alkaline water may be increased. If it is less than 0.0, the compound dissolved in a soluble solvent may not be sufficiently precipitated, and the compound may be decomposed to lower the purity.
[0015]
The temperature of the alkaline water does not hinder the precipitation even at room temperature, but it is preferable to use the alkaline water after cooling to about 0 to 15 ° C. for efficiency.
When the temperature is higher than room temperature, the precipitation efficiency of the compound is reduced, and the yield may be reduced. If the temperature is lower than 0 ° C., there is no problem in precipitating the compound, but the precipitating effect is saturated, which may be disadvantageous in terms of thermoeconomics.
[0016]
The alkaline water at the above pH and the above temperature is used in an amount of 200 to 10,000 parts by weight, preferably 4,000 to 8,100 parts by weight, based on 100 parts by weight of the solvate and / or hydrate of the compound represented by the formula (I). Use about 000 parts by weight.
When the amount of alkaline water exceeds 10,000 parts by weight, there is no problem in precipitating the compound, but it is not preferable from the viewpoint of handling and economy, and when the amount is less than 200 parts by weight, the compound is sufficiently removed. Precipitation may not be possible, and the compound may remain in a soluble solvent, which may cause a decrease in yield.
By adding the above alkaline water to a soluble solvent in which a solvate and / or hydrate of a benzimidazole compound is dissolved, fine water crystals of the compound are precipitated.
[0017]
The precipitated crystals are collected by filtration or the like, washed with water or the like as necessary, and then dried at a low temperature of less than 50 ° C. to obtain white crystals of a slightly water-containing benzimidazole compound having a water content of 0.1% or less. Can be obtained.
When the drying temperature is 50 ° C. or higher, the possibility that the compound is decomposed is increased, and the purity may be reduced. When the temperature is too low, the drying time may be increased, or the cooling temperature may be reduced. Since the cost may be high, the lower limit is preferably about room temperature.
A preferable drying temperature is about 35 to 45 ° C.
This drying is preferably performed under reduced pressure in order to further shorten the drying time, and the degree of reduced pressure is suitably 1 to 100 mmHg, preferably about 5 to 30 mmHg.
A drying time at such a temperature and reduced pressure of about 8 to 14 hours is sufficient.
[0018]
【Example】
Example 1
10 g of 2-[(3-methyl-4-<< 2,2,2-trifluoroethoxy >> pyridin-2-yl) methylsulfinyl] benzimidazole having a water content of 1.5% was stirred in 60 g of dimethylformamide at room temperature. Dissolved.
The solution was filtered to remove insolubles, and the obtained filtrate was poured into 600 g of aqueous ammonia having a pH of about 9 and a temperature of about 10 ° C. while stirring, and the precipitated crystals were collected by filtration.
The crystals were washed with 50 g of water and dried at 40 ° C. for 12 hours under reduced pressure of about 15 mmHg to give 2-[(3-methyl-4-<< 2,2,2-trifluoroethoxy) pyridine-2. 9.3 g of white crystals of [-yl) methylsulfinyl] benzimidazole were obtained [yield in terms of a dehydrated product (a product obtained by removing the water content of the original << crystal >>) of 94.4%).
The physical properties of the obtained white crystal were as follows.
[0019]
Melting point: 177.4 ° C (decomposition)
Moisture: 0.04% (Karl Fischer coulometric method with Hiranuma Seisakusho's product name "AQV-7S")
Figure 2004002230
In the above elemental analysis values, only the determination of fluorine is a value measured by an oxygen flask combustion method.
[0020]
Example 2
20 g of 2-[(3-methyl-4-<< 2,2,2-trifluoroethoxy >> pyridin-2-yl) methylsulfinyl] benzimidazole ethanol 0.9% water hydrate was added to tetrahydro It was dissolved by stirring at 35 ° C. in 150 g of furan.
The solution was filtered to remove insolubles, and the obtained filtrate was poured into 1200 g of aqueous ammonia at a pH of about 9.5 and about 10 ° C. with stirring, and the precipitated crystals were collected by filtration.
The crystals were washed with 120 g of water and dried at 45 ° C. under a reduced pressure of about 15 mmHg to give 2-[(3-methyl-4-<< 2,2,2-trifluoroethoxy >> pyridin-2-yl) 9.3 g of white crystals of [methylsulfinyl] benzimidazole were obtained [yield in terms of dehydrated product: 94.4%].
[0021]
When the water content of the obtained white crystal was measured in the same manner as in Example 1, it was 0.03%.
[0022]
【The invention's effect】
According to the method for producing the benzimidazole-based compound of the present invention, the compound having a water content of 0.1% or less can be obtained without raising the temperature to an unnecessarily high level and thus minimizing the decomposition of the benzimidazole-based compound. It can be produced with high purity and extremely high yield.
Moreover, the manufacturing process is extremely simple and industrially significant.

Claims (3)

式(I)で示される化合物の溶媒和物および/または水和物を可溶性の溶媒に溶解し、アルカリ性水により該化合物を結晶化させ、低温乾燥することを特徴とする微水ベンズイミダゾール系化合物の製法。
Figure 2004002230
A solvate and / or hydrate of the compound represented by the formula (I) in a soluble solvent, crystallizing the compound with alkaline water, and drying at a low temperature; Recipe.
Figure 2004002230
可溶性の溶媒が、ジメチルホルムアミドおよび/またはテトラハイドロフランであることを特徴とする請求項1に記載の微水ベンズイミダゾール系化合物の製法。The method for producing a benzimidazole-based compound according to claim 1, wherein the soluble solvent is dimethylformamide and / or tetrahydrofuran. 低温乾燥の際の温度が、50℃未満であることを特徴とする請求項1または2に記載の微水ベンズイミダゾール系化合物の製法。The method according to claim 1 or 2, wherein the temperature at the time of low-temperature drying is lower than 50 ° C.
JP2002160105A 2002-05-31 2002-05-31 Production method of fine water benzimidazole compounds Expired - Lifetime JP4115751B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2002160105A JP4115751B2 (en) 2002-05-31 2002-05-31 Production method of fine water benzimidazole compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002160105A JP4115751B2 (en) 2002-05-31 2002-05-31 Production method of fine water benzimidazole compounds

Publications (2)

Publication Number Publication Date
JP2004002230A true JP2004002230A (en) 2004-01-08
JP4115751B2 JP4115751B2 (en) 2008-07-09

Family

ID=30429639

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002160105A Expired - Lifetime JP4115751B2 (en) 2002-05-31 2002-05-31 Production method of fine water benzimidazole compounds

Country Status (1)

Country Link
JP (1) JP4115751B2 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006030936A1 (en) * 2004-09-13 2006-03-23 Takeda Pharmaceutical Company Limited Method and apparatus for producing oxidized compound
EP1681056A1 (en) * 2005-01-14 2006-07-19 Krka Tovarna Zdravil, D.D., Novo Mesto Process for preparing lansoprazole
JP2008545768A (en) * 2005-06-08 2008-12-18 レツク・フアーマシユーテイカルズ・デー・デー Crystalline solvate of omeprazole sodium
US7678816B2 (en) 2003-02-05 2010-03-16 Teva Pharmaceutical Industries Ltd. Method of stabilizing lansoprazole
CN102180866A (en) * 2011-05-23 2011-09-14 中山大学 New crystal form of lansoprazole and preparation method and application thereof
CN103012369A (en) * 2011-05-23 2013-04-03 中山大学 Lansoprazole N crystal form and preparation method and application thereof

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7678816B2 (en) 2003-02-05 2010-03-16 Teva Pharmaceutical Industries Ltd. Method of stabilizing lansoprazole
JP2012121897A (en) * 2004-09-13 2012-06-28 Takeda Chem Ind Ltd Method and apparatus for producing oxidized compound
JPWO2006030936A1 (en) * 2004-09-13 2008-05-15 武田薬品工業株式会社 Method and apparatus for producing oxide compound
WO2006030936A1 (en) * 2004-09-13 2006-03-23 Takeda Pharmaceutical Company Limited Method and apparatus for producing oxidized compound
KR101376360B1 (en) * 2004-09-13 2014-03-20 다케다 야쿠힌 고교 가부시키가이샤 Method and apparatus for producing oxidized compound
CN102775388A (en) * 2004-09-13 2012-11-14 武田药品工业株式会社 Method and apparatus for producing oxidized compound
JP5173191B2 (en) * 2004-09-13 2013-03-27 武田薬品工業株式会社 Method and apparatus for producing oxide compound
US9346783B2 (en) 2004-09-13 2016-05-24 Takeda Pharmaceutical Company Limited Method and apparatus for producing oxidized compound
US8592598B2 (en) 2004-09-13 2013-11-26 Takeda Pharmaceutical Company Limited Method of producing a crystal of an imidazole compound
WO2006074952A1 (en) * 2005-01-14 2006-07-20 Krka, Tovarna Zdravil, D.D., Novo Mesto Process for preparing lansoprazole
EP1681056A1 (en) * 2005-01-14 2006-07-19 Krka Tovarna Zdravil, D.D., Novo Mesto Process for preparing lansoprazole
EP2308492A1 (en) * 2005-01-14 2011-04-13 KRKA, tovarna zdravil, d.d., Novo mesto Process for preparing lansoprazole
EA015043B1 (en) * 2005-01-14 2011-04-29 Крка, Товарна Здравил, Д.Д., Ново Место Process for preparing lansoprazole
JP2008545768A (en) * 2005-06-08 2008-12-18 レツク・フアーマシユーテイカルズ・デー・デー Crystalline solvate of omeprazole sodium
CN102180866A (en) * 2011-05-23 2011-09-14 中山大学 New crystal form of lansoprazole and preparation method and application thereof
CN103012369A (en) * 2011-05-23 2013-04-03 中山大学 Lansoprazole N crystal form and preparation method and application thereof

Also Published As

Publication number Publication date
JP4115751B2 (en) 2008-07-09

Similar Documents

Publication Publication Date Title
JP3377218B2 (en) Omeprazole sodium salt
JP4573154B2 (en) A new crystalline form of cefdinir
JP2002523411A (en) A new salt form of pantoprazole
RU2345075C2 (en) Method of obtaining pharmaceutical remedies and compounds obtained by claimed method
JP2010090174A (en) New nateglinide crystal
CN105111189B (en) A kind of compound of pantoprazole sodium monohydrate sphaerocrystal and preparation method thereof
JP2001039975A (en) Crystal of sulfoxide derivative and its production
JP2004002230A (en) Method for producing microaqueous benzimidazole compound
WO2011004387A2 (en) Process for the preparation of dexlansoprazole polymorphic forms
JP2006232859A (en) Method of stabilizing lansoprazole
TW201617336A (en) Crystal of potassium ion competitive acid blocker and preparation method thereof
US20090198066A1 (en) Amorphous esomeprazole hydrate
JP2007238596A (en) Direct process for forming amino acid dihydrochloride
JPS6341465A (en) Method for producing cimetidine polymorph B
JP2004536810A5 (en)
JP2007008918A (en) Process for manufacturing paroxetine hydrochloride hemihydrate
KR20130140918A (en) New process for the preparation of crystal modifications for use in the preparation of esomeprazole sodium salt
JP2011519840A (en) Preparation of 1,7&#39;-dimethyl-2&#39;-propyl-2,5&#39;-bi-1H-benzimidazole
JP7330180B2 (en) Method for producing tipiracil hydrochloride crystal form III
CA2504796A1 (en) Polymorphs of pantoprazole sodium salt and process for the preparation thereof
US20100121068A1 (en) Process for preparing rabeprazole sodium
JP3931884B2 (en) Tablet manufacturing method
US20090082572A1 (en) Process for amorphous esomeprazole
KR101170940B1 (en) A process for preparing a crystalline pantoprazole sodium sesquihydrate
JP3900302B2 (en) Method for producing crystalline calcium calcium aspartate

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040402

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080321

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20080415

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20080416

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110425

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4115751

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110425

Year of fee payment: 3

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110425

Year of fee payment: 3

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120425

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130425

Year of fee payment: 5

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term